psma-617 has been researched along with cabazitaxel* in 4 studies
1 trial(s) available for psma-617 and cabazitaxel
Article | Year |
---|---|
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [
Previously, results from the TheraP trial showed that treatment with lutetium-177 [. TheraP was a multicentre, open-label, randomised phase 2 trial that recruited men with metastatic castration-resistant prostate cancer after treatment with docetaxel who were suitable for cabazitaxel from 11 hospitals in Australia. Participants were required to be 18 years old or older; have adequate haematological, renal, and liver function; and an Eastern Cooperative Oncology Group performance status of 0-2. Participants were randomly assigned (1:1) using a centralised system using minimisation with a random component and that stratified patients by disease burden, previous treatment with enzalutamide or abiraterone, and study site. Patients were either given cabazitaxel (20 mg/m. In men with metastatic castration-resistant prostate cancer, PSMA-PET SUVmean was predictive of higher likelihood of favourable response to [. Prostate Cancer Foundation of Australia, Endocyte (a Novartis Company), Australian Nuclear Science and Technology Organisation, Movember Foundation, It's a Bloke Thing, CAN4CANCER, The Distinguished Gentleman's Ride. Topics: Adolescent; Adult; Australia; Fluorodeoxyglucose F18; Humans; Male; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2022 |
3 other study(ies) available for psma-617 and cabazitaxel
Article | Year |
---|---|
Topics: Carcinoma; Castration; Humans; Male; Prostate; Prostatic Neoplasms | 2023 |
Topics: Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2023 |
Re: [
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2021 |